---
title: "GRI Bio, Inc. 2Q 2026: Net income $(1.64) M, EPS $(0.91) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295930174.md"
description: "GRI Bio reported a Q2 2026 net loss of $1.64M and diluted EPS of $(0.91), with no operating revenue. The company secured cash through Q2 2027 via recent financing but requires additional funding for later-stage trials. Clinically, its Phase 2a trial for GRI-0621 met safety endpoints and showed supportive signals. The FDA granted Orphan Drug Designation for GRI-0621 in IPF on June 18, 2026."
datetime: "2026-08-14T11:51:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295930174.md)
  - [en](https://longbridge.com/en/news/295930174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295930174.md)
generator: "portal-rs"
---

# GRI Bio, Inc. 2Q 2026: Net income $(1.64) M, EPS $(0.91) — 10-Q Summary

GRI Bio, Inc. reported a net loss of $(1.64) M for the second quarter of 2026, with diluted loss per share of $(0.91). The company did not report operating revenue for the quarter and said recent financing activity provides cash into Q2 2027 while additional funding will be needed to advance later-stage trials.

**Financial Highlights**

-   Net income: $(1.64) M for 2Q 2026, compared with $(2.89) M in 2Q 2025.
-   Diluted earnings per share: $(0.91) for 2Q 2026, versus $(36.72) in 2Q 2025.
-   Revenue: Not reported for 2Q 2026 (no operating revenues disclosed in Part 1 Item 1/Item 2).

**Business Highlights**

-   Clinical milestone: The Phase 2a trial of GRI-0621 met its primary safety endpoint and showed supportive biomarker, RNAseq and pharmacodynamic signals consistent with activity.
-   Regulatory progress: The FDA granted Orphan Drug Designation for GRI-0621 in idiopathic pulmonary fibrosis (IPF) on June 18, 2026.
-   Operational focus: Management prioritized resources toward GRI-0621; development of GRI-0803 is limited pending additional funding, with IND-enabling work targeted for H1 2027.
-   Clinical findings: Company reported signals of anti-fibrotic activity, trends toward improved FVC, and immune-modulation versus placebo in the Phase 2a data.
-   Capital and runway: At-the-market program and recent offerings provided cash to fund operations through Q2 2027, but additional financing will be required to support further clinical trials.

Original SEC Filing: GRI Bio, Inc. \[ GRI \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GRI.US](https://longbridge.com/en/quote/GRI.US.md)

## Related News & Research

- [GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation](https://longbridge.com/en/news/297190781.md)
- [Igua Sergipe board signs off Q2 2026 financial results](https://longbridge.com/en/news/297932404.md)
- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**